Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma
Kartik Sehgal(Beth Israel Deaconess Medical Center), Jochen H. Lorch(Northwestern University), Julia Schiantarelli(Broad Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), N. Besson(Dana-Farber Cancer Institute), Mofei Liu(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Cora A. Ricker(Dana-Farber Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute), Gerard M. Doherty(Mass General Brigham), Justine A. Barletta(Brigham and Women's Hospital), Θεοδώρα Παππά(Brigham and Women's Hospital), Brendan Reardon(Broad Institute), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Erik K. Alexander(Mass General Brigham), Jihye Park(Broad Institute), Stephanie M. Jones(Harvard University), Emma L. Welsh(Brigham and Women's Hospital), Anne O’Neill(International Breast Cancer Study Group), Kee‐Young Shin(Dana-Farber Cancer Institute)
Cited by 38
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k